AIM, Cocrystal, CEL-SCI, Beroni Pursue Coronavirus Treatment Candidates

Investors have sent shares of three biopharmas zooming since Friday afternoon based on announcements that they are developing treatments for SARS-CoV-2, while a U.S./Australian biopharma today disclosed plans to advance a nanobody-based treatment candidate into clinical trials next month.